GSK, Cytiva, and Lonza are among 20 companies looking to develop technologies aimed at lowering the cost of cell and gene therapy production. Over 20 companies have been brought together by the Cell and Gene Therapy Catapult (CGT Catapult) to assess multiple process analytical technologies (PAT), which are new or frequently used in other sectors. This is the first consortium of this scale with the 20 companies consisting of technology providers, therapy developers, charities, and pharmaceutical firms. The consortium has…

Apeiron Biologics makes high level changes to management and supervisory board. Meanwhile, there are changes at Relief Therapeutics. Sit back, put your feet up, and enjoy BioProcess Insider’s Ins & outs. Up first in this week’s Ins & Outs is Apeiron Biologics, a biotech firm that develops immunotherapies for respiratory diseases and cancer. According to the company, it is expanding its management board and supervisory board to meet the firm’s growth requirements. Romana Gugenberger has been appointed as chief medical and…

Danaher will increase its lipid service offerings through the acquisition of Canadian-based technology and solution firm Precision Nanosystems. The deal, of which financials have not been disclosed, sees lipid nanoparticle tech firm Precision Nanosystems (PNI) join Danaher Corporation’s family of life science companies, which include Cytiva and Pall. PNI offers consumables, equipment, and reagents to help manufacture lipid nanoparticles for the delivery of genetic medicines, including messenger RNA (mRNA) therapeutics and vaccines. Through the acquisition, Danaher gains PNI’s GenVoy delivery…

ADC Therapeutics’ recently approved cancer treatment Zynlonta will be commercially manufactured by Avid Bioservices in Tustin, California.   Contract development manufacturing organization (CDMO) Avid Bioservices will manufacture the monoclonal antibody portion of the antibody-drug conjugate (ADC) Zynlonta (loncastuximab tesirine), which received US Food and Drug Administration (FDA) approval in April. Avid has provided ADC Therapeutics with clinical manufacturing services since 2017. However, the firm will now undertake commercial manufacturing activities for Zynlonta, which is used to treat patients with relapsed or…

Moderna has inked a deal with Samsung Biologics and Novavax has signed a memorandum of understanding with SK bioscience to provide global access to their vaccines. Novavax has not yet received authorization for its recombinant protein COVID-19 vaccine candidate NVX-CoV2373 but it is prepping for commercialization, signing a non-binding memorandum of understanding (MoU) with the Ministry of Health and Welfare of Korea and contract development manufacturing organization (CDMO) SK bioscience. Under the terms of the agreement, SK bioscience will continue…

Biogen will use Gingko Bioworks’ mammalian cell programming platform to help advance its AAV-based vector manufacturing. Under the terms of the agreement, Gingko will provide Biogen with access to its cell programming capabilities and platform. Gingko will use its bioengineering resources and biomanufacturing space to enhance Biogen’s AAV production titers in its gene therapy manufacturing processes. Biogen will pay $5 million upfront, but Gingko has the potential to receive $115 million depending on research, development, and commercial milestones. Biogen says…